The pharmaceutical industry is currently making strenuous efforts to reduce its impact on the environment. Such efforts necessarily intensify the scrutiny of emissions from pharmaceutical manufacturing processes along with the impact of associated mitigation technology. Optimising solvent abatement and volatile organic compound (VOC) recovery processes is a small but important part of the overall challenge and calls for reliable, cost-effective solutions with a low environmental footprint.

This whitepaper introduces the Cryo-Condap system, a cryogenic solvent abatement and VOC recovery technology from Air Products with proven application in the pharmaceutical industry. It examines the technology's merits relative to alternative technologies within the context of ‘Net Zero’ solvent abatement and VOC recovery. A case study illustrates the application of the Cryo-Condap technology to reduce VOC emissions at a biopharmaceutical site to levels far below those specified by the EPA and at the same time eliminate the production of waste carbon.

Download the Whitepaper here.

 Sponsored by